Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROACTIVE

Financiado

Cerrado

PROposing Action to ConTrol and Impede betacoronaVirus Emergencies

The COVID-19 pandemic caught the world unprepared. Vaccines and monoclonal antibodies (mAbs), developed in record time, mitigated the health and economic damages, however our reaction has always been one step behind the virus evol... ver más

31/10/2028

TLS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FONDAZIONE TOSCANA LIFE SCIENCES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-31

ERC-2022-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TLS

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SOLVE Sustainable COVID-19 Vaccination for Long-term Vaccine Immun... 9M€ Cerrado

EPIC-CROWN-2 Equine Polyclonal antibodies Immunotherapy against COVID-19/... 9M€ Cerrado

PDC2021-121307-I00 IMPACTO DEL VECTOR MVA-ISG15 EN LA INFECION POR SARS-COV-2/C... 150K€ Cerrado

EUR2022-134042 EL PAPEL DE LAS MUTACIONES FENOTIPICAS EN LA EVASION DE ANTI... 90K€ Cerrado

PID2019-109870RB-I00 BLOQUEAR LA ENTRADA DE VIRUS CON ENVUELTA EN CELULAS INMUNES... 363K€ Cerrado

AB-AG-INTERACT Learning the interaction rules of antibody-antigen binding 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-10-31
Fecha Fin: 2028-10-31

Líder del proyecto

FONDAZIONE TOSCANA LIFE SCIENCES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The COVID-19 pandemic caught the world unprepared. Vaccines and monoclonal antibodies (mAbs), developed in record time, mitigated the health and economic damages, however our reaction has always been one step behind the virus evolution, and emerging variants repeatedly escaped our interventions. The omicron variant escaped humoral immunity generated by most vaccines and mAbs by mutating immunodominant epitopes. The extremely potent mAb developed by our laboratory also lost potency against omicron.  Here we propose to develop vaccines and monoclonals neutralizing existing and future variants of SARS-CoV-2 and other coronaviruses, by targeting immunologically subdominant regions which are less susceptible to antigenic variation. We will isolate mAbs from individuals who had infection and multiple vaccinations, whose repertoire is enriched in B cells encoding broadly neutralizing antibodies, to build a map of the broadly shared epitopes. Structural prediction and clustering of the immune repertoire through deep neural networks will be used to improve the breadth of coverage of the mAbs. The Monte Carlo-based sequence design of Rosetta and free energy perturbation calculations will be used to in-silico design protein-binding proteins and identify newly designed immunogens which can be loaded on nanoparticles and used as vaccines. This approach will provide broadly protective mAbs and vaccines proactively designed to neutralize all variants of SARS-CoV-2 and new coronaviruses that are very likely to jump from animals to humans in the future. If successful, the approach to map subdominant epitopes and use of genomic and structural information to design mAbs and vaccines targeting subdominant, broadly conserved epitopes, will pave the way to approach other pathogens with high antigenic variability such as influenza and HIV viruses, Plasmodium spp. and antibiotic resistant bacteria. This will strongly increase European competitiveness in fighting infections.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores